GM2 gangliosidosis
https://www.sciencedirect.com/science/article/pii/S1096719226004476
GM2 gangliosidoses and Niemann–Pick type C (NPC) disease are rare inherited conditions that damage the brain and nervous system over time. People living with these disorders can experience difficulties with movement, balance, speech, swallowing, learning, and seizures. While treatments are available to help slow NPC disease, there are currently no disease-modifying therapies approved for GM2 gangliosidoses, highlighting the need for new treatment options. The RAINBOW study investigated the safety and potential benefits of a new oral medicine called nizubaglustat. Thirteen participants aged 12 years and older with either GM2 gangliosidoses or NPC disease took part in the phase 2 clinical trial. Participants initially received either nizubaglustat or a placebo for 12 weeks, before most continued treatment with nizubaglustat for up to 18 months. Researchers found that nizubaglustat was generally well tolerated, with most side effects being mild or moderate. The medicine also reduced levels of glucosylceramides, fatty substances that build up in these diseases, suggesting it was successfully targeting the underlying disease process. Over the 18-month treatment period, many participants showed improvements or remained stable in measures of balance, movement, and neurological function. Importantly, seizure frequency also decreased in those receiving treatment. Although this was a small study involving only 13 participants, the results are encouraging. Nizubaglustat appeared to have a favourable safety profile while showing signs that it may slow disease progression and improve symptoms in both GM2 gangliosidoses and NPC disease. These findings support further investigation in larger phase 3 clinical trials to confirm whether nizubaglustat can become an effective treatment for people living with these rare neurological disorders.